Luca Magnani

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2012514/publications.pdf

Version: 2024-02-01

61	3,036	147801	168389
papers	citations	31 h-index	53 g-index

67	67	67	6038
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Poised epigenetic states and acquired drug resistance in cancer. Nature Reviews Cancer, 2014, 14, 747-753.	28.4	252
2	Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology, 2012, 51, 151-156.	1.9	203
3	PBX1 Genomic Pioneer Function Drives ERÎ± Signaling Underlying Progression in Breast Cancer. PLoS Genetics, 2011, 7, e1002368.	3.5	167
4	Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1490-9.	7.1	149
5	Pioneer factors: directing transcriptional regulators within the chromatin environment. Trends in Genetics, 2011, 27, 465-474.	6.7	138
6	Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts. Nature Communications, 2019, 10, 130.	12.8	116
7	Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. Nature Communications, 2015, 6, 10044.	12.8	108
8	APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer. Cell Reports, 2015, 13, 108-121.	6.4	105
9	TGF-Î² induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. Nature Communications, 2018, 9, 1845.	12.8	101
10	Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer. Nature Medicine, 2018, 24, 1469-1480.	30.7	98
11	FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression. Scientific Reports, 2019, 9, 1505.	3.3	96
12	Spearhead Nanometric Field-Effect Transistor Sensors for Single-Cell Analysis. ACS Nano, 2016, 10, 3214-3221.	14.6	95
13	Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy. Nature Communications, 2019, 10, 3840.	12.8	93
14	Guidelines for the selection of functional assays to evaluate the hallmarks of cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1866, 300-319.	7.4	89
15	Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERÎ± metastatic breast cancer. Nature Genetics, 2017, 49, 444-450.	21.4	77
16	Smallâ€vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: Two subsets of giant cell arteritis. Arthritis and Rheumatism, 2012, 64, 549-556.	6.7	69
17	GMTR: Two-dimensional geo-fit multitarget retrieval model for Michelson Interferometer for Passive Atmospheric Sounding/Environmental Satellite observations. Applied Optics, 2006, 45, 716.	2.1	67
18	Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells. Breast Cancer Research, 2014, 16, R62.	5.0	66

#	Article	IF	Citations
19	Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 5929-5938.	7.0	66
20	Brg1 Is Required for Cdx2-Mediated Repression of Oct4 Expression in Mouse Blastocysts. PLoS ONE, 2010, 5, e10622.	2.5	53
21	Chromatin and epigenetic determinants of estrogen receptor alpha (ESR1) signaling. Molecular and Cellular Endocrinology, 2014, 382, 633-641.	3.2	53
22	In vitro and in vivo derived porcine embryos possess similar, but not identical, patterns of Oct4, Nanog, and Sox2 mRNA expression during cleavage development. Molecular Reproduction and Development, 2008, 75, 1726-1735.	2.0	52
23	Brief Report: Interleukinâ€6 as an Inflammatory Mediator and Target of Therapy in Chronic Periaortitis. Arthritis and Rheumatism, 2013, 65, 2469-2475.	6.7	51
24	LRH-1 Governs Vital Transcriptional Programs in Endocrine-Sensitive and -Resistant Breast Cancer Cells. Cancer Research, 2014, 74, 2015-2025.	0.9	48
25	The pioneer factor PBX1 is a novel driver of metastatic progression in ERÎ±-positive breast cancer. Oncotarget, 2015, 6, 21878-21891.	1.8	45
26	Differential remodeling of monoâ€•and trimethylated H3K27 during porcine embryo development. Molecular Reproduction and Development, 2009, 76, 1033-1042.	2.0	43
27	SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERÎ± breast cancer. Nature Communications, 2019, 10, 2115.	12.8	42
28	Identification of PBX1 Target Genes in Cancer Cells by Global Mapping of PBX1 Binding Sites. PLoS ONE, 2012, 7, e36054.	2.5	40
29	Nuclear receptors and chromatin: an inducible couple. Journal of Molecular Endocrinology, 2014, 52, R137-R149.	2.5	36
30	KPNA7, an oocyte- and embryo-specific karyopherin?subtype, is required for porcine embryo development. Reproduction, Fertility and Development, 2012, 24, 382.	0.4	35
31	DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through notch hyper-activation. Oncotarget, 2015, 6, 22467-22479.	1.8	33
32	Extensive and systematic rewiring of histone post-translational modifications in cancer model systems. Nucleic Acids Research, 2018, 46, 3817-3832.	14.5	31
33	Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking. Nature Communications, 2020, 11, 1446.	12.8	28
34	Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer. Cancer Research, 2016, 76, 3989-4001.	0.9	27
35	The transcriptional co-repressor TLE3 suppresses basal signaling on a subset of estrogen receptor Î± target genes. Nucleic Acids Research, 2014, 42, 11339-11348.	14.5	26
36	Expression of eukaryotic elongation initiation factor 1A differentially marks zygotic genome activation in biparental and parthenogenetic porcine embryos and correlates with in vitro developmental potential. Reproduction, Fertility and Development, 2008, 20, 818.	0.4	23

#	Article	IF	Citations
37	Manipulation of SMARCA2 and SMARCA4 transcript levels in porcine embryos differentially alters development and expression of SMARCA1, SOX2, NANOG, and EIF1. Reproduction, 2009, 137, 23-33.	2.6	21
38	LMTK3 Represses Tumor Suppressor-like Genes through Chromatin Remodeling in Breast Cancer. Cell Reports, 2015, 12, 837-849.	6.4	21
39	MIPAS-ENVISAT limb-sounding measurements: trade-off study for improvement of horizontal resolution. Applied Optics, 2004, 43, 5814.	2.1	19
40	Gene expression and development of early pig embryos produced by serial nuclear transfer. Molecular Reproduction and Development, 2009, 76, 555-563.	2.0	19
41	ChIP-BIT: Bayesian inference of target genes using a novel joint probabilistic model of ChIP-seq profiles. Nucleic Acids Research, 2016, 44, e65-e65.	14.5	15
42	The many faces of cancer evolution. IScience, 2021, 24, 102403.	4.1	15
43	Chromatin landscape and endocrine response in breast cancer. Epigenomics, 2012, 4, 675-683.	2.1	14
44	Developmental arrest induced in cleavage stage porcine embryos following microinjection of mRNA encodingBrahma (Smarca 2), a chromatin remodeling protein. Molecular Reproduction and Development, 2007, 74, 1262-1267.	2.0	11
45	Global H3K9 dimethylation status is not affected by transcription, translation, or DNA replication in porcine zygotes. Molecular Reproduction and Development, 2010, 77, 420-429.	2.0	10
46	Clinicopathological Birdâ€™s-Eye View of Left Atrial Myocardial Fibrosis in 121 Patients With Persistent Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007588.	4.8	9
47	Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers. Rheumatology and Therapy, 2022, 9, 891-905.	2.3	8
48	Developmental capacity of porcine nuclear transfer embryos correlate with levels of chromatinâ€remodeling transcripts in donor cells. Molecular Reproduction and Development, 2008, 75, 766-776.	2.0	7
49	New indications for biological therapies. Internal and Emergency Medicine, 2011, 6, 1-9.	2.0	7
50	ChIPing away at breast cancer. Lancet Oncology, The, 2012, 13, 1185-1187.	10.7	5
51	Level 2 near-real-time analysis of MIPAS measurements on ENVISAT. , 2003, , .		4
52	Management of Systemic Sclerosis Patients in the COVID-19 Era: The Experience of an Expert Specialist Reference Center. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2021, 15, 117954842110013.	0.9	4
53	Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study. Journal of Personalized Medicine, 2021, 11, 580.	2.5	4
54	Going off the grid: ERÎ± breast cancer beyond estradiol. Journal of Molecular Endocrinology, 2016, 57, F1-F5.	2.5	2

#	Article	IF	Citations
55	Chromatin Immunoprecipitation and High-Throughput Sequencing (ChIP-Seq): Tips and Tricks Regarding the Laboratory Protocol and Initial Downstream Data Analysis. Methods in Molecular Biology, 2018, 1767, 271-288.	0.9	2
56	Long-term methotrexate use in rheumatoid arthritis patients: real-world data from the MARTE study. Minerva Medica, 2021, 112, 246-254.	0.9	2
57	Leg Ulcers Associated With Giant Cell Arteritis Relapse. International Journal of Lower Extremity Wounds, 2013, 12, 69-70.	1.1	1
58	Geo-fit approach to the analysis of limb-scanning satellite measurements. , 2002, 4539, 369.		0
59	Stem Cells in Translational Cancer Research. Stem Cells International, 2015, 2015, 1-2.	2.5	0
60	Histone Posttranslational Modifications in Breast Cancer and Their Use in Clinical Diagnosis and Prognosis. , 2016, , 467-477.		0
61	Fundamental Pathways in Breast Cancer 3: Estrogen Biology. , 2017, , 19-26.		0